Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients

Pediatric Blood and Cancer

Volumn 62, Issue 4, 2015, Pages 704-709

  Seif, Alix E ^a,b   Walker, Dana M ^c   Li, Yimei ^a   Huang, Yuan Shung V ^a   Kavcic, Marko ^d   Torp, Kari ^a   Bagatell, Rochelle ^a,b   Fisher, Brian T ^a,b   Aplenc, Richard ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Cardiotoxicity after cancer therapy; Dexrazoxane; Epidemiology; Secondary malignancy

Indexed keywords

ANTHRAQUINONE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RAZOXANE; ANTHRACYCLINE; CARDIOTONIC AGENT; CARDIOTOXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLACK PERSON; BONE CANCER; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; ICD-9; INDUCTION CHEMOTHERAPY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SCHOOL CHILD; CHEMICALLY INDUCED; FACTUAL DATABASE; INFANT; LEUKEMIA, MYELOID, ACUTE; NEOPLASMS, SECOND PRIMARY; RISK FACTOR; UNITED STATES;

ADOLESCENT; ADULT; ANTHRACYCLINES; CARDIOTONIC AGENTS; CARDIOTOXINS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DEXRAZOXANE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84923171765     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25043     Document Type: Article

References (28)

1. Ginsberg JP, Cnaan A, Zhao H, et al. Using health-related quality of life measures to predict cardiac function in survivors exposed to anthracyclines. J Clin Oncol 2004; 22:3149-3155.
2. van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. Eur J Cancer 2006; 42:3191-3198.
3. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-1677.
4. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309:2371-2381.
5. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332:1738-1743.
6. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979-4990.
7. Silber JH, Jakacki RI, Larsen RL, et al. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993; 21:477-479.
8. Cvetkovic RS, Scott LJ. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005; 65:1005-1024.
9. Hasinoff BB. The interaction of the cardioprotective agent ICRF-187 [+)-1, 2-bis(3, 5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 1989; 26:378-385.
10. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319:745-752.
11. Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 1998; 25:43-47.
12. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14:362-372.
13. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145-153.
14. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11:950-961.
15. Schiavetti A, Castello MA, Versacci P, et al. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: Preliminary results. Pediatr Hematol Oncol 1997; 14:213-222.
16. US Food and Drug Administration. Dexrazoxane hydrochloride (ANDA 200752) approval letter, Octobter 19, 2011. 2011; http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory-apphist. Accessed September 12, 2013.
17. US Food and Drug Administration. Dexrazoxane hydrochloride (ANDA 076068) approval letter, September 28, 2004. 2004; http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory-apphist. Accessed September 12, 2013.
18. Walker DM, Fisher BT, Seif AE, et al. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr Blood Cancer 2013; 60:616-620.
19. Committee for Medicinal Products for Human Use. European Medicines Agency recommends restricting the use of dexrazoxane-containing medicines. 2011; http://www.ema.europa.eu. Accessed September 15, 2013.
20. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25:493-500.
21. Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008; 26:1106-1111.
22. Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the children's oncology group. Leukemia 2010; 24:355-370.
23. Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011; 47:1373-1379.
24. Feudtner C, Hays RM, Haynes G, et al. Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. Pediatrics 2001; 107:E99.
25. Kavcic M, Fisher BT, Torp K, et al. Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database. Pediatr Blood Cancer 2013; 60:508-511.
26. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-763.
27. Tebbi CK, Mendenhall NP, London WB, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:1259-1265.
28. Kim MY, Goldberg JD. The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trials. Stat Med 2001; 20:2065-2078.